Filtered By:
Drug: Rituxan

This page shows you your search results in order of relevance. This is page number 8.

Order by Relevance | Date

Total 7090 results found since Jan 2013.

Does opening access to oral disease modifying therapy increase rates of initiation and reduce disease-related medical costs in a national population of patients with multiple sclerosis? (P3.403)
Conclusions:Once access to oral DMTs was simplified, there was an increase in oral DMT initiation rates. Oral DMTs were associated with decreased medical costs and increased pharmacy costs.Study Supported by: Novartis Pharmaceuticals Corporation.Disclosure: Dr. Ko has received personal compensation for activities with Novartis Pharmaceuticals Corporation as an employee. Dr. Kantor has received personal compensation for activities with Avanir, Bayer, Biogen, EMD Serono, Abbvie, Genzyme, Malinckrodt, Novartis, Otsuka, and Sandoz as consulting services and/or speakig honoraria. Dr. DeClue has nothing to disclose. Dr. Drzayich...
Source: Neurology - April 17, 2017 Category: Neurology Authors: Ko, J., Kantor, D., DeClue, R., Antol, D. D., Casebeer, A. W., Li, Y., Stemkowski, S., Varga, S., Cave, J., Herrera, V. Tags: Economic Implications of Multiple Sclerosis Source Type: research

A nationwide evaluation of off-label drug utilization in Turkey
Conclusion: It is noteworthy that OLDU applications showed demographical and institutional differences. It is expected that this study will provide important contributions to physicians working in the relevant area with respect to treatment alternatives of diseases with treatment challenges. PMID: 29156868 [PubMed]
Source: Turkish Journal of Medical Sciences - November 22, 2017 Category: General Medicine Tags: Turk J Med Sci Source Type: research

Medical treatment in thyroid eye disease in 2020.
Abstract Thyroid eye disease (TED) affects 25% of patients with Graves' hyperthyroidism, where 1 in 20 patients has active, moderate-to-severe disease that will require medical treatment for reducing TED activity and severity. Intravenous corticosteroid has been the mainstay of treatment for active moderate-to-severe TED. With improved understanding of the pathophysiology of TED, immunotherapy targeting different molecular pathways including T cells, B cells, cytokines and cell surface receptors have been investigated in randomised clinical trials. This review provides an overview of the current advances in medica...
Source: The British Journal of Ophthalmology - May 22, 2020 Category: Opthalmology Authors: Khong JJ, McNab A Tags: Br J Ophthalmol Source Type: research

Cost-effectiveness analysis of treatment regimens with obinutuzumab plus chemotherapy in Japan for untreated follicular lymphoma patients.
Conclusions: The cost-effectiveness of G + Chemo is acceptable in Japan. Differences in the direct medical costs among treatment regimen groups were mostly due to hospitalization costs. This is probably because many Japanese hematologists choose inpatient treatments over outpatient treatments in CHOP-based induction therapy. PMID: 32620061 [PubMed - as supplied by publisher]
Source: Journal of Medical Economics - July 7, 2020 Category: Health Management Tags: J Med Econ Source Type: research

Primary Central Nervous System Lymphoma: Clinical Characteristics, Treatment Options and Therapeutic Outcome in 36 Patients. A Single Center Experience
CONCLUSIONS: A difference in CR and PFS favored a more aggressive protocol, but the toxicity of the multiagent combinations was significantly higher. The prognosis in younger was better than in older patients, with higher rates of CR, PFS, and OS, although not statistically significant. Overall treatment outcomes are encouraging; however, there is a real need for an adaptive approach for older patients and balancing among the effectiveness and side effects.PMID:36309861
Source: The Israel Medical Association Journal - October 30, 2022 Category: General Medicine Authors: Miri Zektser Anat Rabinovich Uri Grinbaum Tzvi Porges Aya Gozlan Anna Gourevitch Kayed Al-Athamen Orit Barrett Ido Peles Tehila Kaisman-Elbaz Etai Levi Source Type: research